| Literature DB >> 24336208 |
Celeste M Karch1,2, Sheng Chih Jin1, Carlos Cruchaga1,2, Bruno A Benitez1, Yefei Cai1, Rita Guerreiro3,4, Oscar Harari1, Joanne Norton1, John Budde1, Sarah Bertelsen1, Amanda T Jeng1, Breanna Cooper1, Tara Skorupa1, David Carrell1, Denise Levitch1, Simon Hsu1, Jiyoon Choi1, Mina Ryten3,5, Celeste Sassi3,4, Jose Bras3, Raphael J Gibbs3,4, Dena G Hernandez3,4, Michelle K Lupton6,7, John Powell6, Paola Forabosco8, Perry G Ridge9, Christopher D Corcoran10,11, JoAnn T Tschanz11,12, Maria C Norton11,12,13, Ronald G Munger13,14, Cameron Schmutz9, Maegan Leary9, F Yesim Demirci15, Mikhil N Bamne15, Xingbin Wang15, Oscar L Lopez16,17, Mary Ganguli18, Christopher Medway19, James Turton19, Jenny Lord19, Anne Braae19, Imelda Barber19, Kristelle Brown19, Pau Pastor20,21,22, Oswaldo Lorenzo-Betancor20, Zoran Brkanac23, Erick Scott24, Eric Topol24, Kevin Morgan19, Ekaterina Rogaeva25, Andy Singleton4, John Hardy3, M Ilyas Kamboh16,16,18, Peter St George-Hyslop25,26, Nigel Cairns2,27, John C Morris27,28,29, John S K Kauwe9, Alison M Goate1,2,28,29,30.
Abstract
Genome-wide association studies (GWAS) have identified several risk variants for late-onset Alzheimer's disease (LOAD). These common variants have replicable but small effects on LOAD risk and generally do not have obvious functional effects. Low-frequency coding variants, not detected by GWAS, are predicted to include functional variants with larger effects on risk. To identify low-frequency coding variants with large effects on LOAD risk, we carried out whole-exome sequencing (WES) in 14 large LOAD families and follow-up analyses of the candidate variants in several large LOAD case-control data sets. A rare variant in PLD3 (phospholipase D3; Val232Met) segregated with disease status in two independent families and doubled risk for Alzheimer's disease in seven independent case-control series with a total of more than 11,000 cases and controls of European descent. Gene-based burden analyses in 4,387 cases and controls of European descent and 302 African American cases and controls, with complete sequence data for PLD3, reveal that several variants in this gene increase risk for Alzheimer's disease in both populations. PLD3 is highly expressed in brain regions that are vulnerable to Alzheimer's disease pathology, including hippocampus and cortex, and is expressed at significantly lower levels in neurons from Alzheimer's disease brains compared to control brains. Overexpression of PLD3 leads to a significant decrease in intracellular amyloid-β precursor protein (APP) and extracellular Aβ42 and Aβ40 (the 42- and 40-residue isoforms of the amyloid-β peptide), and knockdown of PLD3 leads to a significant increase in extracellular Aβ42 and Aβ40. Together, our genetic and functional data indicate that carriers of PLD3 coding variants have a twofold increased risk for LOAD and that PLD3 influences APP processing. This study provides an example of how densely affected families may help to identify rare variants with large effects on risk for disease or other complex traits.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24336208 PMCID: PMC4050701 DOI: 10.1038/nature12825
Source DB: PubMed Journal: Nature ISSN: 0028-0836 Impact factor: 49.962